Therapeutic effect of saffron extract in patients with chronic schizophrenia

Therapeutic effect of saffron extract on negative, positive and general symptoms of schizophrenia in comparison with placebo in patients with chronic schizophrenia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210525051404N1

Enrollment

Registered

2021-08-10

Start date

2021-08-23

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophernia. Schizophrenia

Interventions

Intervention 1: Intervention group: Treated with 15 mg capsule of saffron extract twice a day with routine treatments. Intervention 2: Control group: Placebo is prepared in the form of a capsule that

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Schizophrenia according to the DSM-V-TR criteria stable symptoms Age between 18 and 65 years

Exclusion criteria

Exclusion criteria: General medical problems (including coronary artery disease, metabolic syndrome, and neurological diseases) Drug abuse Taking antiplatelet drugs Taking herbal medicines Sensitivity to saffron

Design outcomes

Primary

Measure	Time frame
Negative symptoms of schizophernia. Timepoint: Beginning of research and end of research (fourth week). Method of measurement: Positive and Negative Syndrome Scale.;Positive symptoms of schizophrenia. Timepoint: Beginning of research and end of research (fourth week). Method of measurement: Positive and Negative Syndrome Scale.;General symptoms of schizophrenia. Timepoint: Beginning of research and end of research (fourth week). Method of measurement: Positive and Negative Syndrome Scale.	—

Measure

Time frame

Negative symptoms of schizophernia. Timepoint: Beginning of research and end of research (fourth week). Method of measurement: Positive and Negative Syndrome Scale.;Positive symptoms of schizophrenia. Timepoint: Beginning of research and end of research (fourth week). Method of measurement: Positive and Negative Syndrome Scale.;General symptoms of schizophrenia. Timepoint: Beginning of research and end of research (fourth week). Method of measurement: Positive and Negative Syndrome Scale.

—

Secondary

Measure	Time frame
Symptoms of anxiety. Timepoint: Beginning of research and end of research (fourth week). Method of measurement: Hamilton Anxiety Scale.;Symptoms of depression. Timepoint: Beginning of research and end of research (fourth week). Method of measurement: Hamilton Depression Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdi Haji Rezaei

Kerman University of Medical Sciences

mahdi_hajirezaei@yahoo.com+98 34 3211 0409

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026